Selectivity Profiling: Unbiased Analysis of Compound Selectivity in Drug Discovery

Sponsored by:

Date:

February 19, 2026

Time (PT):

11:00 AM

Duration (min):

Join us for an in-depth webinar exploring how CETSA Selectivity Profiling empowers smarter decision-making in drug discovery.

Drew Nager will share how Pfizer Oncology leverages Pelago Bioscience's CETSA Selectivity service to accelerate project progression, while Laurence Arnold from Pelago Bioscience will present case studies demonstrating the impact of the service across diverse targets, modalities, and stages of discovery.

The service offers an unbiased, proteome-wide view of compound interactions accessing biologically relevant targets that conventional selectivity panels often miss.

Powered by automated sample preparation and high-throughput LC/MS proteomics, the service enables analysis of approximately 100 samples/day with quantification of >5,000 proteins in lysate. As a result, you obtain actionable insights within 10 working days, accelerating the DMTA cycle and supporting data-driven lead optimization.

Live Q&A: Bring your questions and explore how CETSA Selectivity can be seamlessly integrated into your discovery programs.

All intellectual property rights, including copyrights and trademarks, relating to CETSA are owned by Pelago Bioscience AB.

Presenters

Drew Nager

Pfizer (Oncology)

Director of Systems Biology

Dr. Nager is part of Pfizer’s Oncology Research Unit and works on the discovery of the next generation of small-molecule, biologic, and antibody drug conjugate therapeutics. His research team leverages proteomic and transcriptomic approaches to better understand targets and candidate drugs.

Laurence Arnold

Pelago Bioscience

Head of R&D

Laurence Arnold is the Head of R&D at Pelago Bioscience. With a background in Protein biochemistry and Biophysics he and his team leverage CETSA data to determine actionable insights from cellular drug:protein interactions alongside developing the next generation of products stemming from target engagement.

Tove Boström

Pelago Bioscience

Product Manager

Tove Boström is a Product Manager at Pelago Bioscience, contributing to the development of CETSA-based solutions for drug discovery. With a strong background in proteomics and mass spectrometry, she supports the growing proteomics offering and helps turn customer needs into practical, effective applications.

Pelago Bioscience

Pelago Bioscience supports drug discovery teams with their patented CETSA® (Cellular Thermal Shift Assay) technology, delivering biologically relevant insights directly from natural cell environments. As the pioneers of CETSA, they provide fast, actionable data to minimize risks, prioritize compounds, and drive progress.

Content Partners

Scientist.com

Scientist.com is the world’s largest and first platform built for the intricacies of scientific outsourcing.

We help pharmaceutical and biotechnology organizations discover, engage, manage, and scale relationships with the providers that support every stage of the pipeline—from discovery and preclinical research to clinical development, manufacturing, medical affairs, and commercialization. Through a centralized platform, organizations can access a global network of 6,000+ providers, streamline sourcing and procurement workflows, maintain compliance, manage supplier relationships, and leverage data-driven insights to make faster, more informed decisions.

Today, Scientist.com supports more than 130 life science organizations, including 24 of the world's top 30 pharmaceutical companies, helping teams reduce operational complexity, accelerate timelines, and bring innovations to patients faster. Our mission is to make it possible to cure all human disease by 2050.

‍

Topics

Pharmacology

Selectivity Profiling: Unbiased Analysis of Compound Selectivity in Drug Discovery

Presenters

Drew Nager

Laurence Arnold

Tove Boström

Sponsor

Pelago Bioscience

Content Partners

Scientist.com

Topics

Watch Now

Related Content

Advancing the Manufacture of Mesenchymal Stromal Cells and Derived Extracellular Vesicles in Stirred-Tank Bioreactors Through Enhanced Bioprocess Control

From Clinical Data to Actionable Assets for Pharmaceutical R&D

Screening the Unscreenable: Expanding the Reach of Drug Discovery

Advancing the Manufacture of Mesenchymal Stromal Cells and Derived Extracellular Vesicles in Stirred-Tank Bioreactors Through Enhanced Bioprocess Control

Precision in Human Biological Samples: Leveraging Regulatory Rigor and Deep Data for Advanced Disease Research

Detecting Early Synaptic Failure in Prion Disease Using Organoid Models

Improving Preclinical Decision-Making in Obesity and CKD with Translational In Vivo Phenotyping

Bridging Mouse Models and Human Inflammatory Bowel Disease: in vivo Pharmacology, Histology and Biomarkers

Screening the Unscreenable: Expanding the Reach of Drug Discovery

High-Throughput-qPCR and Transcriptomics: Powering the Next Generation of Drug Discovery

From Clinical Data to Actionable Assets for Pharmaceutical R&D

Strategies to Optimize Commercialization of Oncology Treatments for Younger Adults

Patient Data: Opportunities for Rare Diseases, Cell and Gene Therapies, and Oncology

Trials and tribulations of drug development

Webinar Series: Early patient preferences for patient-focused drug development

Looking Beyond Survival Data: Understanding the Value of Non-OS Endpoints in Oncology Reimbursement Decision-Making

Cutting Edge Conversations: Discovering New Innovations in Oncology

Translational Success in Inflammasome Drug Discovery: How Advanced Models and Integrated Assays Can Reduce Attrition

How to Avoid Expensive Redesign Cycles in Antibody Discovery

Recent Advances in Crystalline Polymorphism Research in Drug Development

Improving Confidence in Thyroid Hormone Disruption Assessment Using a Novel Human-Relevant In Vitro Model

Accelerating Antibody Discovery: Integrating Microfluidics, HT Expression, and Early Developability Platform

Beyond Exposure: Integrating PK/PD for Translational Predictive Power

Fulfilling the Gap: Innovative Critical Reagents for Non-Human Primate Preclinical Studies

Advancing ADC Development: Leveraging AI and Translational Preclinical Models to Improve Clinical Predictability

Scaling AAV9 Manufacturing: A Blueprint for Clinical-Grade Gene Therapy Production

Human iPSC-Derived Sensory Neurons for Functional Sensory Biology and Pharmacology Research

From Biopsy to Better Decisions: Patient-Derived Organoids Predict Treatment Response in Metastatic Colorectal Cancer

Accelerating Conjugation Process Development for Next-Generation ADCs: Key Considerations and Platform Strategies

Epigenomics at 360 in Liquid Biopsy: Approaches and Case Studies for Biomarker Discovery and Drug Development

The Sound of Science: Mapping the Tumor Microenvironment for Advanced Therapeutic Strategies

Next-Generation TCR-Like Antibodies With Improved Specificity Profiles

ADC Payload-Linker CMC Process Development Strategy

De-Risking Immunotherapy Targets with Next-Gen HLA Discovery Platforms

Clinical Applications of Optical Cerebral Blood Flow Imaging

ADCs on The Horizon: The Performance and Prospect of Cell Line Development Platform ‚Äî AmigoCHO

Selectivity Profiling: Unbiased Analysis of Compound Selectivity in Drug Discovery

Building New Approach Methodologies for Angiogenesis and Vascularized Models

Using ALS Patient-Derived Motor Neurons to Study TDP-43 Mislocalization

Vevo Ask The Experts: Oncology Imaging

hiPSC-Cardiomyocyte Platforms Enabling Comprehensive Cardiac Toxicity and Drug Efficacy Evaluation

Protein-Protein Interaction (PPI) Landscape - Sequence-to-Affinity Heatmaps for High-Throughput Antibody Optimization

Human Biological Samples in Research: Quality, Compliance, and Clinical Relevance

Combination Therapy for Glioblastoma: A Personalized, AI-Driven Approach

In Vivo panCAR Therapy Using Circular RNA for the Treatment of Autoimmune Disease

From Single Domain to Single B: Leveraging Biointron's Expertise for Antibody Discovery Success

Beyond Checkpoints: Strategic Use of CDX Models in Emerging IO Therapies

Non CYP Mediated Metabolism Pathways and In Vitro Evaluation Strategies

Uniting biology and digital drug discovery to identify new therapeutic opportunities in neurodegeneration

Enhance Your Tissue Processing Efficiency with the STEMprep Tissue Dissociator

Novel Applications of the Cellular Thermal Shift Assay (CETSA) Provide New Insights for Drug Discovery

Vaccine-Boosting CAR T Cells Against Solid Tumors

Exploring the iPSC-Derived Neuronal-Glia Co-culture System: A Powerful Drug Discovery Platform for Studying Neurodegenerative Diseases

Integrating Regulatory Guidance and Sustainable Skin Procurement for Consistent Execution of In Vitro Permeation Testing

Launch Event: Propelling Boundaries - Innovative Technologies in Early Drug Discovery

Advances in Preclinical Research using Human Co-culture Models: Applications in Immunology, Infectious Disease, and Oncology

Cell-Based Assays for Immuno-oncology

Artificial Intelligence in Preclinical Research: Pathology, Biospecimens, and Model Selection

CAR Finder - A Platform for Rapid CAR T Cell Screening

CRISPR Gene Editing in Primary T Cells: A Case Study in the Fight Against HIV

Improved Clearance Predictions for Aldehyde Oxidase Substrates Using TruVivo, a Novel Human Hepatocyte Model

Introduction to Bispecific Antibodies and Their Production

The Hidden Variable in Your Intestinal Organoids: Enhancing Differentiation for a More Predictive Model

Integrating Functionalized Multi-omics in Oncology Drug Discovery

Fresh or Cryopreserved Leukopaks? Assessing the Impact of Different Storage Conditions on Leukopak Stability

Breaking the Bottleneck: Harnessing Proteomics Services to Overcome Challenges in Clinical Research

Leveraging Genomic, Preclinical, and Drug Response Data in the Age of AI

Biomarkers from Bench to Bedside: Tools, Targets, and Translational Insights